USD 11.52
(2.45%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 3.74 Billion USD | -3.4% |
2022 | 3.88 Billion USD | -1.07% |
2021 | 3.92 Billion USD | -17.41% |
2020 | 4.74 Billion USD | -13.7% |
2019 | 5.5 Billion USD | 8.24% |
2018 | 5.08 Billion USD | -14.01% |
2017 | 5.91 Billion USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q3 | 923 Million USD | -1.7% |
2024 Q2 | 939 Million USD | -1.88% |
2024 Q1 | 957 Million USD | 4.59% |
2023 Q1 | 958 Million USD | 7.52% |
2023 Q3 | 907 Million USD | -6.3% |
2023 Q2 | 968 Million USD | 1.04% |
2023 Q4 | 915 Million USD | 0.88% |
2023 FY | 3.74 Billion USD | -3.4% |
2022 Q1 | 1 Billion USD | 0.1% |
2022 FY | 3.88 Billion USD | -1.07% |
2022 Q4 | 891 Million USD | -9.63% |
2022 Q3 | 986 Million USD | -1.1% |
2022 Q2 | 997 Million USD | -0.89% |
2021 Q2 | 1.01 Billion USD | 10.6% |
2021 FY | 3.92 Billion USD | -17.41% |
2021 Q1 | 915 Million USD | -32.87% |
2021 Q4 | 1 Billion USD | 1.41% |
2021 Q3 | 991 Million USD | -2.08% |
2020 Q4 | 1.36 Billion USD | 26.44% |
2020 Q3 | 1.07 Billion USD | 1.13% |
2020 Q2 | 1.06 Billion USD | -14.17% |
2020 Q1 | 1.24 Billion USD | 0.0% |
2020 FY | 4.74 Billion USD | -13.7% |
2019 FY | 5.5 Billion USD | 8.24% |
2018 FY | 5.08 Billion USD | -14.01% |
2017 FY | 5.91 Billion USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AbbVie Inc. | 45.53 Billion USD | 91.77% |
Bristol-Myers Squibb Company | 34.31 Billion USD | 89.077% |
Bristol-Myers Squibb Company Ce | 34.31 Billion USD | 89.077% |
Johnson & Johnson | 58.6 Billion USD | 93.605% |
Eli Lilly and Company | 27.04 Billion USD | 86.14% |
Merck & Co., Inc. | 43.98 Billion USD | 91.48% |
Novartis AG | 34.18 Billion USD | 89.037% |
Pfizer Inc. | 28.8 Billion USD | 86.99% |